Companies Cerus Corp
Cerus (CERS): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Cerus Corp’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers30th pct.Of 20 peer CEOs
CEO pay, last three years
- $3,660,472FY2023
- $2,975,617FY2024
- $3,794,657FY2025
CEO total pay was $3,794,657 in fiscal 2025, up from $2,975,617 in fiscal 2024.
FY2025: salary $793,750 · bonus $0 · stock awards $2,242,585 · option awards $0
Executives and directors
Richard Benjamin · Chief Medical OfficerChrystal Jensen · General CounselKevin Green · CFOVivek Jayaraman · COOWilliam Greenman · CEOAnn Lucena · Independent DirectorDaniel N. Swisher Jr · Independent DirectorDean Gregory · Independent DirectorEric Bjerkholt · Independent DirectorFrank Witney, Ph.D · Independent DirectorGail Schulze · Independent DirectorHua Shan, M.D., Ph.D · Independent DirectorJami Dover Nachtsheim · Independent DirectorTimothy L. Moore · Independent Director
Frequently asked questions
Who was the highest-paid executive at Cerus Corp in fiscal 2025?
As disclosed, William Greenman (President and Chief Executive Officer) was the highest-paid executive at Cerus Corp in fiscal 2025, with total compensation of $3,794,657.
How does Cerus Corp's chief executive pay compare to its disclosed peer group?
As disclosed, William Greenman's total compensation ranked at the 30th percentile of Cerus Corp's disclosed peer group.
What is Cerus Corp's CEO-to-median employee pay ratio?
As disclosed, Cerus Corp's CEO-to-median employee pay ratio was 17.54:1.
How did shareholders vote on Cerus Corp's executive compensation?
As disclosed, 91.69% of shareholders supported Cerus Corp's executive compensation in the latest say-on-pay vote.
How much does Cerus Corp spend in total on board compensation for fiscal 2025?
As disclosed, Cerus Corp reported total board compensation of $1,134,574 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| William Greenman | $793,750 | $0 | $2,242,585 | $0 | $756,000 | $0 | $2,322 | $3,794,657 |
| President and Chief Executive Officer | ||||||||
| Vivek Jayaraman | 565,768 | 0 | 1,240,044 | 0 | 395,244 | 0 | 3,142 | 2,204,198 |
| Chief Operating Officer | ||||||||
| Kevin Green | 507,440 | 0 | 918,826 | 0 | 322,890 | 0 | 1,242 | 1,750,398 |
| Chief Financial Officer | ||||||||
| Chrystal Jensen | 487,076 | 0 | 866,753 | 0 | 265,656 | 0 | 2,772 | 1,622,257 |
| Chief Legal Officer, General Counsel and Secretary | ||||||||
| Richard Benjamin | 508,690 | 0 | 713,844 | 0 | 276,911 | 0 | 7,108 | 1,506,553 |
| Chief Medical Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| William Greenman | $3,794,657 | $2,975,617 | $3,660,472 | ↑ +819,040 |
| Vivek Jayaraman | 2,204,198 | 1,483,868 | 1,790,279 | ↑ +720,330 |
| Kevin Green | 1,750,398 | 1,268,994 | 1,461,572 | ↑ +481,404 |
| Chrystal Jensen | 1,622,257 | 1,104,756 | 1,310,087 | ↑ +517,501 |
| Richard Benjamin | 1,506,553 | 1,129,618 | 1,342,282 | ↑ +376,935 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Cerus aims to attract and retain highly qualified executives by providing competitive compensation that aligns with peer companies and rewards performance.
| CEO STI target (% of salary) | 75% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Alpine |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Kevin Green | RSU | 2025-03-06 | — | — | 392,500 | — | $600,525 |
| William Greenman | RSU | 2025-03-06 | — | — | 165,752 | — | 253,585 |
| Kevin Green | RSU | 2025-03-06 | — | — | 80,540 | — | 123,226 |
| Vivek Jayaraman | RSU | 2025-03-06 | — | — | 90,486 | — | 138,444 |
| Richard Benjamin | RSU | 2025-03-06 | — | — | 300,000 | — | 459,000 |
| Chrystal Jensen | RSU | 2025-03-06 | — | — | 385,000 | — | 589,050 |
| Chrystal Jensen | RSU | 2025-03-06 | — | — | 69,577 | — | 106,453 |
| William Greenman | RSU | 2025-03-06 | — | — | 975,000 | — | 1,491,750 |
| Vivek Jayaraman | RSU | 2025-03-06 | — | — | 545,000 | — | 833,850 |
| Richard Benjamin | RSU | 2025-03-06 | — | — | 66,565 | — | 101,844 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Kevin Green | $723,751 | $0 | $0 | 0.0% |
| William Greenman | 1,745,335 | 0 | 0 | 0.0% |
| Vivek Jayaraman | 972,294 | 0 | 0 | 0.0% |
| Richard Benjamin | 560,844 | 0 | 0 | 0.0% |
| Chrystal Jensen | 695,503 | 0 | 0 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Richard Benjamin | Option | 6,563 | 5.76 | — |
| Chrystal Jensen | Option | 6,563 | 5.76 | — |
| Kevin Green | Option | 8,750 | 5.76 | — |
| Vivek Jayaraman | Option | 11,250 | 5.76 | — |
| William Greenman | Option | 27,188 | 5.76 | — |
| Richard Benjamin | RSU | 53,333 | — | 109,866 |
| Chrystal Jensen | RSU | 53,333 | — | 109,866 |
| Richard Benjamin | RSU | 55,000 | — | 113,300 |
| Chrystal Jensen | RSU | 55,000 | — | 113,300 |
| Richard Benjamin | RSU | 55,220 | — | 113,753 |
| Chrystal Jensen | RSU | 55,220 | — | 113,753 |
| Kevin Green | RSU | 61,666 | — | 127,032 |
| Kevin Green | RSU | 63,600 | — | 131,016 |
| Kevin Green | RSU | 63,854 | — | 131,539 |
| Vivek Jayaraman | RSU | 80,000 | — | 164,800 |
| Vivek Jayaraman | RSU | 80,320 | — | 165,459 |
| Richard Benjamin | RSU | 105,600 | — | 217,536 |
| Chrystal Jensen | RSU | 105,600 | — | 217,536 |
| Kevin Green | RSU | 132,000 | — | 271,920 |
| Vivek Jayaraman | RSU | 158,400 | — | 326,304 |
| William Greenman | RSU | 191,666 | — | 394,832 |
| William Greenman | RSU | 192,500 | — | 396,550 |
| William Greenman | RSU | 193,270 | — | 398,136 |
| Richard Benjamin | PSU | 200,000 | — | 412,000 |
| Richard Benjamin | PSU | 220,000 | — | 453,200 |
| Chrystal Jensen | PSU | 220,000 | — | 453,200 |
| Chrystal Jensen | PSU | 250,000 | — | 515,000 |
| Kevin Green | PSU | 255,000 | — | 525,300 |
| Kevin Green | PSU | 266,000 | — | 547,960 |
| Richard Benjamin | RSU | 300,000 | — | 618,000 |
| Vivek Jayaraman | PSU | 320,000 | — | 659,200 |
| Vivek Jayaraman | PSU | 350,000 | — | 721,000 |
| William Greenman | RSU | 379,500 | — | 781,770 |
| Chrystal Jensen | RSU | 385,000 | — | 793,100 |
| Kevin Green | RSU | 392,500 | — | 808,550 |
| Vivek Jayaraman | RSU | 545,000 | — | 1,122,700 |
| William Greenman | PSU | 650,000 | — | 1,399,000 |
| William Greenman | PSU | 770,000 | — | 1,586,200 |
| William Greenman | RSU | 975,000 | — | 2,008,500 |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Frank Witney, Ph.DIndependent · Compensation | $82,524 | $86,400 | $0 | — | $0 | $168,924 |
| Ann LucenaIndependent · Audit · Compensation (Chair) | 72,167 | 86,400 | 0 | — | 0 | 158,567 |
| Eric BjerkholtIndependent · Audit (Chair) | 65,583 | 86,400 | 0 | — | 0 | 151,983 |
| Timothy L. MooreIndependent · Compensation · Not standing for re-election | 63,000 | 86,400 | 0 | — | 0 | 149,400 |
| Jami Dover NachtsheimIndependent · Compensation · Nominating and Corporate Governance (Chair) | 55,000 | 86,400 | 0 | — | 0 | 141,400 |
| Hua Shan, M.D., Ph.DIndependent · Nominating and Corporate Governance | 51,000 | 86,400 | 0 | — | 0 | 137,400 |
| Daniel N. Swisher JrIndependent | 49,500 | 86,400 | 0 | — | 0 | 135,900 |
| Dean GregoryIndependent · Audit | 63,500 | 0 | 0 | — | 0 | 63,500 |
| Gail SchulzeIndependent · Compensation | 27,500 | 0 | 0 | — | 0 | 27,500 |
| William M. GreenmanEmployee director · Board Chair | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $45,000 |
|---|---|
| Annual equity retainer | $150,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 26,000 / 15,000 / 10,000 |
| Stock ownership guideline | We maintain stock ownership guidelines for our non-employee directors and our Chief Executive Officer. More information about our stock ownership guidelines can be found under the sections of this proxy statement entitled “Executive Compensation—Compensation Discussion and Analysis—Executive Compensation Components and Decisions—CEO Stock Ownership Guidelines” and “Director Compensation—Stock Ownership Guidelines.” |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $529,774 |
| Equity awards (grant-date value) | $604,800 |
| All other compensation | $0 |
| Total cost of the board | $1,134,574 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Cerus as a peer
Companies that benchmark against CERS
10 companies name CERS as a compensation peer
- BIOLIFE SOLUTIONS INCBLFSFY2024
- CareDx, Inc.CDNAFY2025
- GeneDx Holdings Corp.WGSFY2025
- InfuSystem Holdings, IncINFUFY2025
- LIFECORE BIOMEDICAL, INC. \DE\LFCRFY2025
- ORASURE TECHNOLOGIES INCOSURFY2025
- SI-BONE, Inc.SIBNFY2025
- SURMODICS INCSRDXFY2024
- SURMODICS INCSRMDFY2024
- ZYNEX INCZYNXFY2024
- ZYNEX INCZYXIFY2024
Each company listed discloses CERS in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named CERS in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
AKBA Akebia TherapeuticsANIK Anika TherapeuticsCDXS Codexis, Inc.ANGO AngioDynamics, Inc.BLFS BioLife Solutions, Inc.COLL Collegium Pharmaceutical, Inc.DVAX Dynavax Technologies CorpHRTX Heron Therapeutics, Inc.INVA Innoviva, Inc.KPTI Karyopharm Therapeutics Inc.MGNX MacroGenics, Inc.MNKD MannKind CorporationOSUR OraSure Technologies, Inc.TVTX Travere Therapeutics, Inc.VNDA Vanda Pharmaceuticals, Inc.MIRM Mirum Pharmaceuticals, Inc.RIGL Rigel Pharmaceuticals, Inc.ARDX Ardelyx, Inc.CDNA CareDX, Inc.OABI OmniAb, Inc.
Peer reciprocity
The companies Cerus Corp names as compensation peers that name it back in their own disclosed peer groups.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Mirum Pharmaceuticals, Inc. | 2025 | Christopher Peetz | $755,000 | $3,683,904 | $4,931,320 | $1,057,000 | $10,441,224 |
| 2 | MannKind Corporation | 2025 | Michael Castagna | 789,436 | 7,689,480 | 0 | 675,757 | 9,300,485 |
| 3 | Travere Therapeutics, Inc. | 2025 | Eric Dube | 854,250 | 3,314,520 | 3,309,384 | 964,125 | 8,457,151 |
| 4 | Dynavax Technologies Corp | 2024 | Ryan Spencer | 835,001 | 4,902,150 | 1,824,299 | 641,907 | 8,210,775 |
| 5 | Ardelyx, Inc. | 2025 | Michael Raab | 797,000 | 2,953,724 | 3,413,948 | 627,638 | 7,796,171 |
| 6 | CareDX, Inc. | 2025 | John Hanna | 693,269 | 5,622,638 | 0 | 852,515 | 7,179,699 |
| 7 | BioLife Solutions, Inc. | 2024 | Roderick de Greef | 744,450 | 5,571,874 | 0 | 655,116 | 7,046,205 |
| 8 | AngioDynamics, Inc. | 2026 | James Clemmer | 828,171 | 3,689,866 | 0 | 1,502,491 | 6,060,145 |
| 9 | Akebia Therapeutics | 2025 | John Butler | 864,010 | 2,164,338 | 2,024,798 | 580,973 | 5,652,339 |
| 10 | Innoviva, Inc. | 2025 | Pavel Raifeld | 600,000 | 2,649,982 | 1,748,882 | 0 | 5,400,197 |
| 11 | Rigel Pharmaceuticals, Inc. | 2025 | Raul Rodriguez | 787,405 | 951,327 | 2,241,570 | 634,649 | 4,658,805 |
| 12 | OraSure Technologies, Inc. | 2025 | Carrie Eglinton Manner | 721,000 | 3,394,188 | 0 | 173,040 | 4,292,228 |
| 13 | Vanda Pharmaceuticals, Inc. | 2025 | Mihael Polymeropoulos | 965,655 | 2,007,000 | 0 | 834,326 | 3,851,468 |
| 14 | OmniAb, Inc. | 2025 | Matthew Foehr | 620,866 | 640,500 | 2,104,620 | 436,289 | 3,811,740 |
| 15 | Cerus Corp | 2025 | William Greenman | 793,750 | 2,242,585 | 0 | 756,000 | 3,794,657 |
| 16 | Heron Therapeutics, Inc. | 2025 | Craig Collard | 689,431 | 946,254 | 1,352,917 | 517,189 | 3,516,291 |
| 17 | Codexis, Inc. | 2025 | Alison Moore | 524,732 | 255,994 | 1,065,223 | 463,125 | 2,323,279 |
| 18 | Karyopharm Therapeutics Inc. | 2025 | Richard Paulson | 770,000 | 838,996 | 241,544 | 350,350 | 2,320,902 |
| 19 | MacroGenics, Inc. | 2025 | Eric Risser | 561,568 | 52,000 | 1,049,386 | 251,900 | 2,078,854 |
| 20 | Anika Therapeutics | 2025 | Stephen Griffin | 500,000 | 1,215,222 | 0 | 0 | 2,033,370 |
| 21 | Collegium Pharmaceutical, Inc. | 2025 | Vikram Karnani | 875,000 | 0 | 0 | 835,406 | 1,715,846 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Cerus Corp | 126% | not disclosed | No | Alpine |
| Akebia Therapeutics | 90% | Options 50 · RSU 25 · MSU 25 | No | Pearl Meyer |
| AngioDynamics, Inc. | 180% | PSU 50 · RSU 50 | No | Meridian Compensation Partners, LLC |
| Anika Therapeutics | 100% | PSU 67 · RSU 33 | No | Willis Towers Watson |
| Ardelyx, Inc. | 105% | Options 50 · RSU 50 | not disclosed | Pearl Meyer |
| BioLife Solutions, Inc. | 88% | RSU 50 · Market-based RSU 50 | Yes — Total Shareholder Return (TSR) | Frederic W. Cook & Co, Inc. |
| CareDX, Inc. | not disclosed | RSU 70 · PRSU 30 | No | Alpine Rewards |
| Codexis, Inc. | 95% | not disclosed | not disclosed | Pearl Meyer |
| Collegium Pharmaceutical, Inc. | 127.3% | RSU 70 · PSU 30 | Yes — relative ranking of the total shareholder return (TSR) of the Company's common stock in 2025, 2026, 2027 and the cumulative three-year performance period (2025-2027) return relative to the TSR of peer companies within the S&P Pharmaceutical Select Industry Index | Alpine Rewards, LLC |
| Dynavax Technologies Corp | 102.5% | Options 34 · RSU 33 · PSU 33 | Yes — Relative Total Stockholder Return (rTSR) ranking vs. Nasdaq Biotechnology Index | Alpine |
| Heron Therapeutics, Inc. | not disclosed | Option 66.67 · RSU 33.33 | not disclosed | Compensia, Inc. |
| Innoviva, Inc. | 105% | not disclosed | not disclosed | Meridian |
| Karyopharm Therapeutics Inc. | 90% | not disclosed | Yes — Relative TSR | Alpine, WTW |
| MacroGenics, Inc. | 85% | not disclosed | not disclosed | Alpine Rewards, LLC |
| MannKind Corporation | 107% | PSU 55 · RSU 45 | Yes — Total Stockholder Return (TSR) relative to Russell 3000 Pharmaceutical & Biotechnology Index | Mercer LLC |
| Mirum Pharmaceuticals, Inc. | 200% | Option 47.2 · PSU 17.6 · RSU 17.6 | No | Alpine Rewards |
| OmniAb, Inc. | not disclosed | not disclosed | not disclosed | Alpine Rewards, LLC |
| OraSure Technologies, Inc. | 24.0% | RSU 50 · PSU 50 | Yes — Relative TSR performance vs peer group | Pay Governance |
| Rigel Pharmaceuticals, Inc. | 124% | Options 75 · RSU 25 | No | Pearl Meyer |
| Travere Therapeutics, Inc. | 150% | not disclosed | No | Aon |
| Vanda Pharmaceuticals, Inc. | 108% | not disclosed | Yes — Relative TSR | Willis Towers Watson |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-02 | 120,905,509 | 10,952,287 | 629,704 | 91.69% | Passed |
| 2025 | 2025-06-03 | 104,504,639 | 9,321,156 | 206,346 | 91.81% | Passed |
| 2024 | 2024-06-05 | 104,504,936 | 9,178,691 | 322,658 | 91.93% | Passed |
| 2023 | 2023-06-07 | 104,045,778 | 13,411,996 | 310,834 | 88.58% | Passed |
| 2022 | 2022-06-01 | 111,539,185 | 4,103,533 | 344,630 | 96.45% | Passed |
| 2021 | 2021-06-02 | 110,706,472 | 4,478,494 | 221,266 | 96.11% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-02 | 91.69%a |
| 2025 | 2025-06-03 | 91.81%b |
| 2024 | 2024-06-05 | 91.93%c |
a. Approved under the standard stated in the filing — “Abstentions and broker non-votes are not counted 95 for the purpose of determining the number of votes cast and will therefore not have any effect on the outcome of the vote on Proposal No.”.
b. Approved under the standard stated in the filing — “Abstentions and broker non-votes are not counted 6 for the purpose of determining the number of votes cast and will therefore not have any effect on the outcome of the vote on Proposal No.”.
c. Approved under the standard stated in the filing — “Abstentions and broker non-votes are not counted for the purpose of determining the number of votes cast and will therefore not have any effect on the outcome of the vote on Proposal No.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 17.54 : 1 |
|---|---|
| CEO total compensation | $3,794,657 |
| Median employee compensation | $216,284 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Vivek Jayaraman | Chief Operating Officer | 2026-05-01 | D | 16,667 | $3 | $50,001 | Common | Form 4 ↗ |
| Vivek Jayaraman | Chief Operating Officer | 2026-05-29 | D | 16,667 | 3 | 50,001 | Common | Form 4 ↗ |
| Eric Bjerkholt | Director | 2026-06-02 | A | 60,000 | 0 | 0 | Common | Form 4 ↗ |
| Frank Witney | Director | 2026-06-02 | A | 60,000 | 0 | 0 | Common | Form 4 ↗ |
| Hua Shan | Director | 2026-06-02 | A | 60,000 | 0 | 0 | Common | Form 4 ↗ |
| Ann Lucena | Director | 2026-06-02 | A | 60,000 | 0 | 0 | Common | Form 4 ↗ |
| Dean Gregory | Director | 2026-06-02 | A | 60,000 | 0 | 0 | Common | Form 4 ↗ |
| Jami Dover Nachtsheim | Director | 2026-06-02 | A | 60,000 | 0 | 0 | Common | Form 4 ↗ |
| Eric Bjerkholt | Director | 2026-06-09 | D | 20,454 | 3 | 53,180 | Common | Form 4 ↗ |
| Kevin Green | Chief Financial Officer | 2026-06-30 | D | 63,600 | 0 | 0 | Common | Form 4 ↗ |
| William Mariner Greenman | Director | 2026-06-30 | D | 101,919 | 3 | 299,937 | Common | Form 4 ↗ |
| Chrystal Jensen | Chief Legal Officer | 2026-06-30 | D | 24,329 | 3 | 71,598 | Common | Form 4 ↗ |
| Vivek Jayaraman | Chief Operating Officer | 2026-06-30 | D | 42,359 | 3 | 124,658 | Common | Form 4 ↗ |
| Kevin Green | Chief Financial Officer | 2026-06-30 | D | 33,676 | 3 | 99,105 | Common | Form 4 ↗ |
| Chrystal Jensen | Chief Legal Officer | 2026-06-30 | D | 55,000 | 0 | 0 | Common | Form 4 ↗ |
| Vivek Jayaraman | Chief Operating Officer | 2026-06-30 | D | 80,000 | 0 | 0 | Common | Form 4 ↗ |
| William Mariner Greenman | Director | 2026-06-30 | D | 192,500 | 0 | 0 | Common | Form 4 ↗ |
| Vivek Jayaraman | Chief Operating Officer | 2026-07-01 | A | 369,686 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Vivek Jayaraman | Chief Operating Officer | 2026-07-01 | A | 554,529 | 0 | 0 | Common | Form 4 ↗ |
| Vivek Jayaraman | Chief Executive Officer | 2026-07-16 | D | 16,666 | 3 | 52,665 | Common | Form 4 ↗ |
| Chrystal Jensen | Chief Legal Officer | 2026-08-17 | D | 30,000 | 3 | 89,529 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (77 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, William Greenman. DEF 14A, filed 2026-04-22. Section “SUMMARY COMPENSATION TABLE” · page 70. As printed: 3,794,657. View filing ↗
- Section 01, Vivek Jayaraman. DEF 14A, filed 2026-04-22. Section “SUMMARY COMPENSATION TABLE” · page 70. As printed: 2,204,198. View filing ↗
- Section 01, Kevin Green. DEF 14A, filed 2026-04-22. Section “SUMMARY COMPENSATION TABLE” · page 70. As printed: 1,750,398. View filing ↗
- Section 01, Chrystal Jensen. DEF 14A, filed 2026-04-22. Section “SUMMARY COMPENSATION TABLE” · page 70. As printed: 1,622,257. View filing ↗
- Section 01, Richard Benjamin. DEF 14A, filed 2026-04-22. Section “SUMMARY COMPENSATION TABLE” · page 70. As printed: 1,506,553. View filing ↗
- Section 03, Kevin Green RSU. DEF 14A, filed 2026-04-22. Section “GRANTS OF PLAN-BASED AWARDS IN FISCAL 2025” · grants of plan-based awards table. View filing ↗
- Section 03, William Greenman RSU. DEF 14A, filed 2026-04-22. Section “GRANTS OF PLAN-BASED AWARDS IN FISCAL 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Kevin Green RSU. DEF 14A, filed 2026-04-22. Section “GRANTS OF PLAN-BASED AWARDS IN FISCAL 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Vivek Jayaraman RSU. DEF 14A, filed 2026-04-22. Section “GRANTS OF PLAN-BASED AWARDS IN FISCAL 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Richard Benjamin RSU. DEF 14A, filed 2026-04-22. Section “GRANTS OF PLAN-BASED AWARDS IN FISCAL 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Chrystal Jensen RSU. DEF 14A, filed 2026-04-22. Section “GRANTS OF PLAN-BASED AWARDS IN FISCAL 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Chrystal Jensen RSU. DEF 14A, filed 2026-04-22. Section “GRANTS OF PLAN-BASED AWARDS IN FISCAL 2025” · grants of plan-based awards table. View filing ↗
- Section 03, William Greenman RSU. DEF 14A, filed 2026-04-22. Section “GRANTS OF PLAN-BASED AWARDS IN FISCAL 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Vivek Jayaraman RSU. DEF 14A, filed 2026-04-22. Section “GRANTS OF PLAN-BASED AWARDS IN FISCAL 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Richard Benjamin RSU. DEF 14A, filed 2026-04-22. Section “GRANTS OF PLAN-BASED AWARDS IN FISCAL 2025” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-04-22. Section “CEO Pay Ratio”. As printed: 17.54 : 1. View filing ↗
- Section 08, Frank Witney, Ph.D. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 168,924. View filing ↗
- Section 08, Ann Lucena. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 158,567. View filing ↗
- Section 08, Eric Bjerkholt. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 151,983. View filing ↗
- Section 08, Timothy L. Moore. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 149,400. View filing ↗
- Section 08, Jami Dover Nachtsheim. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 141,400. View filing ↗
- Section 08, Hua Shan, M.D., Ph.D. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 137,400. View filing ↗
- Section 08, Daniel N. Swisher Jr. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 135,900. View filing ↗
- Section 08, Dean Gregory. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 63,500. View filing ↗
- Section 08, Gail Schulze. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 27,500. View filing ↗
- Section 08, William M. Greenman. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Vivek Jayaraman 2026-05-01. Form 4, filed 2026-05-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Vivek Jayaraman 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Eric Bjerkholt 2026-06-02. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Frank Witney 2026-06-02. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hua Shan 2026-06-02. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ann Lucena 2026-06-02. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dean Gregory 2026-06-02. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jami Dover Nachtsheim 2026-06-02. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Eric Bjerkholt 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Green 2026-06-30. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William Mariner Greenman 2026-06-30. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Chrystal Jensen 2026-06-30. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Vivek Jayaraman 2026-06-30. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Green 2026-06-30. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Chrystal Jensen 2026-06-30. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Vivek Jayaraman 2026-06-30. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William Mariner Greenman 2026-06-30. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Vivek Jayaraman 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Vivek Jayaraman 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Vivek Jayaraman 2026-07-16. Form 4, filed 2026-07-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Chrystal Jensen 2026-08-17. Form 4, filed 2026-08-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-03. Item 5.07 · say-on-pay result. As reported: 91.69% (votes for as printed: 120,905,509). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-09. Item 5.07 · say-on-pay result. As reported: 91.81% (votes for as printed: 104,504,639). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-11. Item 5.07 · say-on-pay result. As reported: 91.93% (votes for as printed: 104,504,936). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 529,774 + equity 604,800 + all other 0 = 1,134,574, summed across the director compensation table rows.
- Mirum Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Mirum Pharmaceuticals, Inc.'s own proxy. As printed: 10,441,224. View filing ↗
- MannKind Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in MannKind Corporation's own proxy. As printed: 9,300,485. View filing ↗
- Travere Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Travere Therapeutics, Inc.'s own proxy. As printed: 8,457,151. View filing ↗
- Dynavax Technologies Corp, Section 10b CEO total. DEF 14A, filed 2025-04-17. CEO total compensation as printed in Dynavax Technologies Corp's own proxy. As printed: 8,210,775. View filing ↗
- Ardelyx, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Ardelyx, Inc.'s own proxy. As printed: 7,796,171. View filing ↗
- CareDX, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in CareDX, Inc.'s own proxy. As printed: 7,179,699. View filing ↗
- BioLife Solutions, Inc., Section 10b CEO total. DEF 14A, filed 2025-07-08. CEO total compensation as printed in BioLife Solutions, Inc.'s own proxy. As printed: 7,046,205. View filing ↗
- AngioDynamics, Inc., Section 10b CEO total. DEF 14A, filed 2026-10-08. CEO total compensation as printed in AngioDynamics, Inc.'s own proxy. As printed: 6,060,145. View filing ↗
- Akebia Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Akebia Therapeutics's own proxy. As printed: 5,652,339. View filing ↗
- Innoviva, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-24. CEO total compensation as printed in Innoviva, Inc.'s own proxy. As printed: 5,400,197. View filing ↗
- Rigel Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-03. CEO total compensation as printed in Rigel Pharmaceuticals, Inc.'s own proxy. As printed: 4,658,805. View filing ↗
- OraSure Technologies, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in OraSure Technologies, Inc.'s own proxy. As printed: 4,292,228. View filing ↗
- Vanda Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Vanda Pharmaceuticals, Inc.'s own proxy. As printed: 3,851,468. View filing ↗
- OmniAb, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in OmniAb, Inc.'s own proxy. As printed: 3,811,740. View filing ↗
- Cerus Corp (subject), Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Cerus Corp's own proxy. As printed: 3,794,657. View filing ↗
- Heron Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Heron Therapeutics, Inc.'s own proxy. As printed: 3,516,291. View filing ↗
- Codexis, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Codexis, Inc.'s own proxy. As printed: 2,323,279. View filing ↗
- Karyopharm Therapeutics Inc., Section 10b CEO total. DEF 14A, filed 2026-04-13. CEO total compensation as printed in Karyopharm Therapeutics Inc.'s own proxy. As printed: 2,320,902. View filing ↗
- MacroGenics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-08. CEO total compensation as printed in MacroGenics, Inc.'s own proxy. As printed: 2,078,854. View filing ↗
- Anika Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Anika Therapeutics's own proxy. As printed: 2,033,370. View filing ↗
- Collegium Pharmaceutical, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Collegium Pharmaceutical, Inc.'s own proxy. As printed: 1,715,846. View filing ↗
- Section 10a, BioLife Solutions, Inc. reciprocity. DEF 14A. BioLife Solutions, Inc. names Cerus Corp in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, OraSure Technologies, Inc. reciprocity. DEF 14A. OraSure Technologies, Inc. names Cerus Corp in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, CareDX, Inc. reciprocity. DEF 14A. CareDX, Inc. names Cerus Corp in its own disclosed peer group (read from its most recent proxy). View filing ↗